Literature DB >> 17404852

Anti-inflammatory effects of pravastatin on Helicobacter pylori-induced gastritis in mice.

Masanori Yamato1, Toshio Watanabe, Kazuhide Higuchi, Koichi Taira, Tetsuya Tanigawa, Masatsugu Shiba, Kazunari Tominaga, Yasuhiro Fujiwara, Nobuhide Oshitani, Koji Takeuchi, Tetsuo Arakawa.   

Abstract

Pravastatin, an HMG-CoA reductase inhibitor, exerts anti-inflammatory effects via several mechanisms including induction of endothelial nitric oxide synthase (eNOS). We investigated the effect of pravastatin on Helicobacter pylori-induced gastritis in mice. Mice with or without H. pylori infection received intraperitoneal pravastatin daily for 1 week. Expression of eNOS mRNA and tumor necrosis factor-alpha mRNA and myeloperoxidase activity in gastric tissue was determined. Myeloperoxidase activity was reduced in a dose-dependent manner by pravastatin, with activity inhibited by 53.5 and 73.7% at doses of 0.3 and 1 mg/kg, respectively. At a dose of 1 mg/kg, pravastatin reduced the level of tumor necrosis factor-alpha mRNA by 52.7%, while it did not affect eNOS expression. Pravastatin had no effects on these inflammatory parameters in uninfected mice. Pravastatin did not affect the viability of H. pylori. In conclusion, pravastatin exerts an anti-inflammatory effect on H. pylori-induced gastritis in mice without affecting eNOS expression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17404852     DOI: 10.1007/s10620-006-9638-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  28 in total

1.  Rosuvastatin, a new HMG-CoA reductase inhibitor, reduces the colonic inflammatory response in dextran sulfate sodium-induced colitis in mice.

Authors:  Yuji Naito; Kazuhiro Katada; Tomohisa Takagi; Hisato Tsuboi; Yutaka Isozaki; Osamu Handa; Satoshi Kokura; Norimasa Yoshida; Hiroshi Ichikawa; Toshikazu Yoshikawa
Journal:  Int J Mol Med       Date:  2006-06       Impact factor: 4.101

2.  Role of neutrophils in a rat model of gastric ulcer recurrence caused by interleukin-1 beta.

Authors:  T Watanabe; T Arakawa; T Fukuda; K Higuchi; K Kobayashi
Journal:  Am J Pathol       Date:  1997-03       Impact factor: 4.307

3.  A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain.

Authors:  A Lee; J O'Rourke; M C De Ungria; B Robertson; G Daskalopoulos; M F Dixon
Journal:  Gastroenterology       Date:  1997-04       Impact factor: 22.682

4.  HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia.

Authors:  C Weber; W Erl; K S Weber; P C Weber
Journal:  J Am Coll Cardiol       Date:  1997-11-01       Impact factor: 24.094

5.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

6.  The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextran-sulfate induced colitis.

Authors:  Makoto Sasaki; Sulaiman Bharwani; Paul Jordan; Takashi Joh; Kenneth Manas; April Warren; Hirohisa Harada; Patsy Carter; John W Elrod; Michael Wolcott; Matthew B Grisham; J Steven Alexander
Journal:  J Pharmacol Exp Ther       Date:  2003-04       Impact factor: 4.030

7.  Monocyte chemotactic protein-1 regulates leukocyte recruitment during gastric ulcer recurrence induced by tumor necrosis factor-alpha.

Authors:  Toshio Watanabe; Kazuhide Higuchi; Masaki Hamaguchi; Masatsugu Shiba; Kazunari Tominaga; Yasuhiro Fujiwara; Takayuki Matsumoto; Tetsuo Arakawa
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2004-06-17       Impact factor: 4.052

8.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

9.  Pentoxifylline prevents indomethacin induced acute gastric mucosal damage in rats: role of tumour necrosis factor alpha.

Authors:  L Santucci; S Fiorucci; M Giansanti; P M Brunori; F M Di Matteo; A Morelli
Journal:  Gut       Date:  1994-07       Impact factor: 23.059

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more
  4 in total

1.  Role of Helicobacter pylori in Gastric Neoplasia.

Authors:  Tetsuya Tsukamoto; Masae Tatematsu
Journal:  Curr Infect Dis Rep       Date:  2014-05       Impact factor: 3.725

2.  Statin Decreases Helicobacter pylori Burden in Macrophages by Promoting Autophagy.

Authors:  Wei-Chih Liao; Mei-Zi Huang; Michelle Lily Wang; Chun-Jung Lin; Tzu-Li Lu; Horng-Ren Lo; Yi-Jiun Pan; Yu-Chen Sun; Min-Chuan Kao; Hui-Jing Lim; Chih-Ho Lai
Journal:  Front Cell Infect Microbiol       Date:  2017-01-17       Impact factor: 5.293

3.  Statin Therapy Is Associated with Reduced Risk of Peptic Ulcer Disease in the Taiwanese Population.

Authors:  Chun-Jung Lin; Wei-Chih Liao; Yu-An Chen; Hwai-Jeng Lin; Chun-Lung Feng; Cheng-Li Lin; Ying-Ju Lin; Min-Chuan Kao; Mei-Zi Huang; Chih-Ho Lai; Chia-Hung Kao
Journal:  Front Pharmacol       Date:  2017-04-28       Impact factor: 5.810

4.  Statins Attenuate Helicobacter pylori CagA Translocation and Reduce Incidence of Gastric Cancer: In Vitro and Population-Based Case-Control Studies.

Authors:  Chun-Jung Lin; Wei-Chih Liao; Hwai-Jeng Lin; Yuan-Man Hsu; Cheng-Li Lin; Yu-An Chen; Chun-Lung Feng; Chih-Jung Chen; Min-Chuan Kao; Chih-Ho Lai; Chia-Hung Kao
Journal:  PLoS One       Date:  2016-01-05       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.